XLO Graph | Xilio Therapeutics, Inc.

XLO Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $18.69M; Research and development $14.56M; Operating expenses $22.18M; Income tax (m).
2026-03-31: Revenue $12.65M; Research and development $19.83M; Operating expenses $26.76M; Income tax (m).
2025-12-31: Revenue $13.69M*; Research and development $18.12M*; Operating expenses $25.52M*; Income tax (m).
2025-09-30: Revenue $19.07M; Research and development $14.32M; Operating expenses $21.00M; Income tax (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$18.69M	$14.56M	$22.18M	(m)	-$6.37M
2026-03-31	$12.65M	$19.83M	$26.76M	(m)	-$9.53M
2025-12-31	$13.69M*	$18.12M*	$25.52M*	(m)	$10.36M*
2025-09-30	$19.07M	$14.32M	$21.00M	(m)	-$16.29M
2025-06-30	$8.08M	$15.33M	$22.45M	(m)	-$15.84M
2025-03-31	$2.93M	$8.27M	$16.78M	(m)	-$13.27M
2024-09-30	$2.26M	$10.76M	$17.02M	(m)	-$14.02M
2024-06-30	$2.36M	$11.22M	$17.06M	(m)	-$13.93M
2024-03-31	(m)	$10.40M	$17.49M	(m)	-$17.20M
2023-09-30	(m)	$11.05M	$17.36M	(m)	-$16.75M
2023-06-30	(m)	$13.22M	$20.12M	(m)	-$19.36M
2023-03-31	(m)	$16.13M	$23.53M	(m)	-$22.65M
2022-09-30	(m)	$13.04M	$20.21M	(m)	-$19.79M
2022-06-30	(m)	$16.25M	$24.55M	(m)	-$24.61M
2022-03-31	(m)	$14.92M	$21.22M	$0.00	-$21.35M
2021-09-30	(m)	$10.47M	$15.96M	(m)	-$16.25M
2021-06-30	(m)	$17.75M	$23.01M	(m)	-$23.18M
2021-03-31	(m)	$11.62M	$16.52M	$0.00	-$16.67M
2020-09-30	(m)	$11.46M	$14.62M	(m)	-$14.82M
2020-06-30	(m)	(m)	(m)	(m)	-$11.51M
2020-03-31	(m)	(m)	(m)	(m)	-$8.12M

Revenue and expense 5 month

Period end	Income tax
2020-05-31	$0.00

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$31.34M	$34.39M	$48.94M	(m)	-$15.90M
2025-06-30	$11.01M	$23.60M	$39.23M	(m)	-$29.11M
2024-06-30	$2.36M	$21.62M	$34.55M	(m)	-$31.13M
2023-06-30	(m)	$29.35M	$43.64M	(m)	-$42.00M
2022-06-30	(m)	$31.17M	$45.78M	$0.00	-$45.97M
2021-06-30	(m)	$29.37M	$39.53M	$0.00	-$39.85M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$30.08M	$37.92M	$60.23M	(m)	-$45.40M
2024-09-30	$4.62M	$32.38M	$51.57M	(m)	-$45.15M
2023-09-30	(m)	$40.40M	$61.00M	(m)	-$58.75M
2022-09-30	(m)	$44.20M	$65.98M	$0.00	-$65.76M
2021-09-30	(m)	$39.84M	$55.49M	$0.00	-$56.10M
2020-09-30	(m)	$26.24M	$33.97M	$0.00	-$34.45M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$43.77M	$56.04M	$85.75M	$0.00	-$35.04M
2024-12-31	$6.34M	$41.21M	$66.93M	$0.00	-$58.24M
2023-12-31	(m)	$52.14M	$79.13M	$0.00	-$76.40M
2022-12-31	(m)	$59.20M	$89.15M	$0.00	-$88.22M
2021-12-31	(m)	$51.19M	$75.04M	$0.00	-$75.80M
2020-12-31	(m)	$43.91M	$54.56M	$0.00	-$55.22M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Serina Therapeutics, Inc. (SER)	United States	$0.054B	-2.35
Clene Inc. (CLNN)	United States	$0.054B	-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)	United States	$0.055B	-2.38
Elicio Therapeutics, Inc. (ELTX)	United States	$0.049B
Lite Strategy, Inc. (LITS)	United States	$0.049B
Dogwood Therapeutics, Inc. (DWTX)	United States	$0.049B
Annovis Bio, Inc. (ANVS)	United States	$0.056B	-1.58
Werewolf Therapeutics, Inc. (HOWL)	United States	$0.047B
NOMAD POWER SOLUTIONS, INC. (NMAD)	United States	$0.058B
Grace Therapeutics, Inc. (GRCE)		$0.046B	-1.83